

**Notice of Special Interest (NOSI): Telehealth in Cancer Care
NOT-CA-21-043
Frequently Asked Questions (FAQ)**

Pre-application Webinar held May 18, 2021

Slides and a videorecording of the Webinar are available at:
<https://cancercontrol.cancer.gov/brp/events/telehealth-in-cancer-care>

Application Instructions and Eligibility

Q1: Are we only permitted to apply for one of the PARs listed on the NOSI solicitation?

A1: Yes. If you would like to apply to the NOSI, you may only submit your application to [PAR-21-190](#), [PAR-21-035](#), [PAR-19-348](#), [PAR-19-350](#) or their reissuances, if applicable at a later date.

Q2: What is the funding opportunity announcement number for the R21?

A2: [PAR-19-350](#)

Q3: Can we apply for this NOSI if we have a K award?

A3: Please check the restrictions of your specific K award to determine your eligibility to apply for any R01 or R21 grant while funded by a K award.

Q4: Will resubmissions be considered after the NOSI expires?

A4: All of the PARs listed on the NOSI accept resubmissions and will do so even after the NOSI expires. You would simply refrain from citing the expired NOSI in the SF424 for your resubmission.

Q5: Can my application have a foreign component?

A5: Foreign components are discouraged due to the unique health care and telehealth context in the U.S.

Scope

Q6: Our planned provider-patient focused telehealth intervention fits within the scope of interventions you identified (targets primary and secondary behavior change). However, the intervention is implemented by health educators (usually MPHs, RDs) not professionals traditionally considered as providers (i.e., MDs, Dos, NPs). Are we eligible to apply?

A6: Yes.

Q7: What do you mean by “stand alone” mHealth studies (described as unresponsive)?

A7: Any mHealth intervention that is a technology-mediated intervention (e.g., text, app) that is not connected to health care delivery or oncology care.

Q8: Under the P50 FOA, "Telehealth and Cancer Care," there is a requirement to propose a pragmatic centerpiece trial and conduct two pilot trials. However, it is not clear if one, or both pilot trials are identified and detailed in the application. Would you know what is expected or would this be a better question for the identified FOA contact?

A8: Please refer all questions about the P50 Telehealth RFA ([RFA-CA-21-029](#)) to the scientific contacts listed on the RFA solicitation. Those requirements do not apply to applications submitted in response to the Telehealth and Cancer Care NOSI.

Q9: Are implementation or effectiveness aims more appropriate?

A9: Either is acceptable and appropriate, but it would depend on your research questions and the current state of science for the intervention.

Q10: Is the NOSI interested in quality assessment and evaluation of care delivery in telehealth?

A10: Yes. A rigorous study design(s) for the quality assessment and evaluation of care delivery in telehealth is essential.

Q11: Would launching a tobacco treatment program via telehealth be appropriate?

A11: Yes.

General

Q12: Where will applications be reviewed?

A12: Applications to NOSIs are not reviewed by Special Emphasis Panels. They will be reviewed by standing Center for Scientific Review (CSR) study sections and triaged based on topic.